In line with updated medical terminology, the text now covers MASLD (metabolic dysfunction-associated steatotic liver disease), formerly known as non-alcoholic fatty liver disease (NAFLD).
Gastrointestinal and Hepatic Manifestations of Coronavirus Infection Enterocolitis and Hepatitis Induced by Cancer Immunotherapy AI and Technology : Features new discussions on using Artificial Intelligence (AI) in endoscopy to improve the detection of GI cancers. Updated Terminology & Conditions : Includes expanded coverage of
Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management (2-Volume Set) Edition: 12th Edition Publish Date: December 2025 Publisher: Elsevier Health Sciences Print Length: 2,560 pages ISBN-13: 978-0443116575 ISBN-10: 0443116571
Significant updates on new treatments for viral hepatitis and evolving biologic therapies for autoimmune liver conditions.
The previous edition focused heavily on the rise of biologics and standard endoscopy. The 12th edition, however, addresses the seismic shifts of the post-pandemic era and new technological breakthroughs.
(metabolic dysfunction-associated steatotic liver disease), formerly known as non-alcoholic fatty liver disease (NAFLD). Therapeutic Updates
– Immune checkpoint inhibitors have transformed oncology, but they frequently cause severe immune‑related adverse events in the gut and liver. This new chapter provides a practical guide to diagnosis, grading, and management of these complications.
The 12th edition bridges the gap between trial data and bedside care. The "hot" factor comes from the —sidebars written by fellows and senior attendings that warn you about rare complications you won't find in the index.
One of the most significant updates in the 12th edition is the comprehensive adoption of updated nomenclature for fatty liver disease.
For GI fellows, practicing physicians, and multidisciplinary care teams, keeping up with this text is essential to maintaining an evidence-based clinical practice. This extensive review dives deep into why the 12th edition is a "hot" topic, what new chapters have been introduced, and how it transforms patient management. Why the 12th Edition is Trending
The textbook is widely distributed via the Elsevier Shop and online retailers like Amazon . While the traditional two-volume physical hardcover set is preferred for libraries and medical offices, the powered by VitalSource or Expert Consult is where this edition shines for daily practice. The digital ecosystem includes:
The text is available through major medical book retailers and directly from the Elsevier Health Store.
This edition is currently available for purchase at major retailers like and directly from Elsevier Evolve Amazon.com included in this new edition?
The 12th edition focuses on rapidly evolving clinical areas and emerging global health issues: Novel Chapters : Includes dedicated coverage for
Edited by a new generation of leaders: Raymond T. Chung, David T. Rubin, and Mel Wilcox.
For more than half a century, one name has stood as the gold standard in gastroenterology and hepatology: Sleisenger and Fordtran’s Gastrointestinal and Liver Disease . The landmark two‑volume masterwork—affectionately dubbed “the Bible of GI/Hepatology” by clinicians around the world—has just released its 12th edition, and the buzz surrounding this latest iteration is palpable. With a new generation of editorial leaders at the helm, dozens of critically updated topics, and a laser focus on the hottest developments in the field, this edition is an absolute must‑have for anyone who manages patients with digestive and liver disorders.
